1st Pharmaceuticals Webinar
Cardio-Oncology: From Adverse Outcome Pathways to Cardiotoxicity Mitigation
The efficacy of anticancer therapies together with early diagnosis has successfully decreased cancer death rates, warranting a longer life to cancer patients. Thus, at present, surviving cancer is not enough and a new meaning has been given to the sentence ‘life after cancer’.
Actually, the quality of life and the full integration of survivors back to society is a new concern amongst the clinical and scientific community. Nevertheless, the adverse effects of anticancer treatments bring a huge burden to patients and health systems.
Cardiotoxicity of anticancer therapies is the second leading cause of death amongst cancer survivors. This adverse effect has been detected in patients since the early use of chemotherapy. Back then, a new field in cardiology, called ‘cardio-oncology’ emerged. Although in the beginning, cardio-oncology aimed to address only the cardiotoxicity of chemotherapy and radiotherapy, at present it focuses on the detection, monitoring, and treatment of cardiovascular disease after classic treatments and also molecular-targeted agents and immune-modulating agents. The ultimate goal is to provide curative or preventive treatment to the cardiovascular complications that arise with cancer treatment without compromising anticancer drug efficacy.
This webinar aims to focus on the adverse outcome pathways of several anticancer treatments and present new pharmacological alternatives that can prevent or cure the cardiotoxicity elicited by anticancer treatments.
Date: 7 December 2022
Time: 11:00 am CET | 5:00 am EST | 6:00 pm CST Asia
Webinar ID: 848 1041 4835
Webinar Secretariat: pharmaceuticals.webinar@mdpi.com